- Home
- COLL vs ZYME Comparison
COLL vs ZYME Comparison
Compare COLL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- ZYME
- Stock Information
- Founded
- COLL 2002
- ZYME 2003
- Country
- COLL United States
- ZYME United States
- Employees
- COLL N/A
- ZYME N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- ZYME Health Care
- Exchange
- COLL Nasdaq
- ZYME Nasdaq
- Market Cap
- COLL 958.8M
- ZYME 867.6M
- IPO Year
- COLL 2015
- ZYME 2017
- Fundamental
- Price
- COLL $31.60
- ZYME $14.25
- Analyst Decision
- COLL Strong Buy
- ZYME Buy
- Analyst Count
- COLL 4
- ZYME 7
- Target Price
- COLL $43.75
- ZYME $19.50
- AVG Volume (30 Days)
- COLL 291.1K
- ZYME 521.9K
- Earning Date
- COLL 08-07-2025
- ZYME 08-07-2025
- Dividend Yield
- COLL N/A
- ZYME N/A
- EPS Growth
- COLL N/A
- ZYME N/A
- EPS
- COLL 1.25
- ZYME N/A
- Revenue
- COLL $664,283,000.00
- ZYME $93,384,000.00
- Revenue This Year
- COLL $20.23
- ZYME $44.71
- Revenue Next Year
- COLL $3.82
- ZYME $34.57
- P/E Ratio
- COLL $25.23
- ZYME N/A
- Revenue Growth
- COLL 17.17
- ZYME 85.05
- 52 Week Low
- COLL $23.23
- ZYME $9.03
- 52 Week High
- COLL $42.29
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- COLL 61.58
- ZYME 64.81
- Support Level
- COLL $31.53
- ZYME $12.77
- Resistance Level
- COLL $32.95
- ZYME $15.00
- Average True Range (ATR)
- COLL 0.88
- ZYME 0.56
- MACD
- COLL 0.06
- ZYME 0.11
- Stochastic Oscillator
- COLL 73.51
- ZYME 73.59
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.